BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

35 related articles for article (PubMed ID: 21586223)

  • 1. Glypican-3-targeted precision diagnosis of hepatocellular carcinoma on clinical sections with a supramolecular 2D imaging probe.
    Han HH; Qiu YJ; Shi YY; Wen W; He XP; Dong LW; Tan YX; Long YT; Tian H; Wang HY
    Theranostics; 2018; 8(12):3268-3274. PubMed ID: 29930728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3 as an emerging molecular target for hepatocellular carcinoma gene therapy.
    Yao M; Wang L; Dong Z; Qian Q; Shi Y; Yu D; Wang S; Zheng W; Yao D
    Tumour Biol; 2014 Jun; 35(6):5857-68. PubMed ID: 24633918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparison of glypican-3 with alpha-fetoprotein as a serum marker for hepatocellular carcinoma: a meta-analysis.
    Xu C; Yan Z; Zhou L; Wang Y
    J Cancer Res Clin Oncol; 2013 Aug; 139(8):1417-24. PubMed ID: 23743582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted glypican-3 gene transcription inhibited the proliferation of human hepatoma cells by specific short hairpin RNA.
    Yu D; Dong Z; Yao M; Wu W; Yan M; Yan X; Qiu L; Chen J; Sai W; Yao D
    Tumour Biol; 2013 Apr; 34(2):661-8. PubMed ID: 23192642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
    Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
    Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies.
    Nassar A; Cohen C; Siddiqui MT
    Diagn Cytopathol; 2009 Sep; 37(9):629-35. PubMed ID: 19405109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma.
    Wu W; Yao DF; Yuan YM; Fan JW; Lu XF; Li XH; Qiu LW; Zong L; Wu XH
    Hepatobiliary Pancreat Dis Int; 2006 Nov; 5(4):538-44. PubMed ID: 17085339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression and its clinicopathological features of tumor rejective antigen 1 in human tissues of hepatocellular carcinoma and liver cirrhosis].
    Zhang H; Huang DF; Wei Q; Hua TY; Li F; Huang JF
    Zhonghua Gan Zang Bing Za Zhi; 2010 Sep; 18(9):661-5. PubMed ID: 20943076
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma.
    Yao M; Yao DF; Bian YZ; Zhang CG; Qiu LW; Wu W; Sai WL; Yang JL; Zhang HJ
    Hepatobiliary Pancreat Dis Int; 2011 Jun; 10(3):289-94. PubMed ID: 21669573
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression features of glypican-3 and its diagnostic and differential values in hepatocellular carcinoma].
    Bian YZ; Yao DF; Zhang CG; Li SS; Wu W; Dong ZZ; Qiu LW; Yu DD
    Zhonghua Gan Zang Bing Za Zhi; 2011 Apr; 19(4):260-5. PubMed ID: 21586223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma.
    Sakamoto M; Mori T; Masugi Y; Effendi K; Rie I; Du W
    Intervirology; 2008; 51 Suppl 1():42-5. PubMed ID: 18544947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3 is a biomarker and a therapeutic target of hepatocellular carcinoma.
    Wang L; Yao M; Pan LH; Qian Q; Yao DF
    Hepatobiliary Pancreat Dis Int; 2015 Aug; 14(4):361-6. PubMed ID: 26256079
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.